NewLink Genetics (NASDAQ:NLNK) Cut to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of NewLink Genetics (NASDAQ:NLNK) from a buy rating to a hold rating in a research note published on Wednesday, Zacks.com reports.

According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “

Separately, ValuEngine cut Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating and three have given a hold rating to the company. NewLink Genetics currently has an average rating of Hold and an average target price of $3.75.

NASDAQ NLNK opened at $1.46 on Wednesday. The company has a 50 day moving average price of $1.60. The company has a current ratio of 13.33, a quick ratio of 13.33 and a debt-to-equity ratio of 0.07. NewLink Genetics has a 52 week low of $1.28 and a 52 week high of $4.95.

NewLink Genetics (NASDAQ:NLNK) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.04. The firm had revenue of $0.11 million for the quarter. NewLink Genetics had a negative return on equity of 38.63% and a negative net margin of 1,691.08%. As a group, equities analysts expect that NewLink Genetics will post -0.1 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Paloma Partners Management Co bought a new stake in NewLink Genetics in the 4th quarter valued at approximately $30,000. Pennsylvania Trust Co bought a new stake in shares of NewLink Genetics during the 1st quarter worth approximately $48,000. Virtu Financial LLC bought a new stake in shares of NewLink Genetics during the 1st quarter worth approximately $60,000. Rhumbline Advisers raised its stake in shares of NewLink Genetics by 41.4% during the 4th quarter. Rhumbline Advisers now owns 40,387 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 11,830 shares in the last quarter. Finally, Two Sigma Advisers LP raised its stake in shares of NewLink Genetics by 22.6% during the 4th quarter. Two Sigma Advisers LP now owns 110,000 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 20,300 shares in the last quarter. Hedge funds and other institutional investors own 34.30% of the company’s stock.

About NewLink Genetics

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.

Further Reading: Compound Interest and Why It Matters When Investing

Get a free copy of the Zacks research report on NewLink Genetics (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.